WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now. [Click here for information about joining the class action] If you’d like t ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) (“Zenas” or the “Company”) securities pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas’ initial public offering held on September 13, 2024 (the “IPO”), charging the Company, certain senior executives and directors, and the underwriters ...

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Capti ...

CLASS PERIOD: This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Zenas BioPharma materially overstated the amount of time that it would ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=144444&from=3  CLASS PERIOD: T ...

WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ:ZBIO) who acquired shares in the company's September 2024 initial public offering ("IPO"). The firm urges affected investors to contact the firm promptly to discuss their legal rights and recovery options. [Click here for information about joining the class action] Or investors should reach out to Molly J. Bowen, a partne ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...

Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, alleging that the company made false and misleading statements in its registration statement related to its September 2024 initial public offering [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Massachusetts on behalf of all individuals and entities who purchased Zenas BioPharma securities during the class period [1]. - Investors have until June 16, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - The complaint alleges that Zenas BioPharma materially overstated the duration it could fund its operations using existing cash and expected net proceeds from the IPO [3]. - It is claimed that the public statements made by the defendants were materially false and misleading at all relevant times and were negligently prepared [3].

You have until June 16, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zenas securities pursuant and/or traceable to Zenas's initial public offering ("IPO"). A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") ...